Novo Nordisk, underway with important launches, reveals $2.58B production investment decision

Amid the essential launches for oral diabetic issues drug Rybelsus and obesity drugs Wegovy, the only dilemma for Novo Nordisk, it appears to be, is assembly developing demand from customers.

On Monday, the Danish drugmaker exposed a shift that will assist achieve that as it will make investments $2.58 billion into growing manufacturing potential.

Novo Nordisk will create three new production facilities and broaden its sprawling site in Kalundborg, Denmark.

Most of the financial commitment will permit Novo Nordisk to increase its manufacture of lively pharmaceutical components (API), it reported. A scaled-down section is reserved for assembly and packaging of the oral and injectable solutions.

Relevant: Demand for Novo Nordisk’s new weight-decline drug Wegovy outstripped early offer, analysts say

The company expects the venture to be finish in 2027. With the enlargement, Novo options to add 400 employment to the Kalundborg internet site, which by now employs 3,200.

“(This) is an critical step in developing and ensuring long term capacity for output of our latest and long run oral injectable products portfolio,” said Henrik Wulff, Novo Nordisk EVP of item offer, excellent and IT, reported in a release. “Kalundborg is presently the cornerstone of our generation of API and the growth of producing capability is crucial to assembly the potential needs of patients.”

The announcement arrives during a interval of a lot growth for the organization. In February, Novo Nordisk disclosed it would shell out $1.3 billion on funds initiatives in 2021 to equipment up to add capacity for lively pharmaceutical components.

Linked: Novo Nordisk plots $1.3B in paying out as it expands API production—and innovations new oral meds

Also in February, Novo Nordisk mentioned it was shelling out $82 million to boost its capability to manufacture Rybelsus in Måløv, Denmark.

The organization not too long ago accomplished a $2 billion API facility in Clayton, N.C. In nearby Durham, the company will shortly open a new oral concluded items facility it purchased in 2019 from troubled Purdue Pharma.